|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Aegera Therapeutics Inc., of Montreal, said data reported at the Federation of Clinical Immunology Societies conference in Boston detailed the induction of apoptosis as a therapeutic intervention to eliminate encepalitogenic T cells. Preclinical findings showed that when symptomatic mice were treated daily with antisense XIAP (X-linked Inhibitor of Apoptosis Protein; AEG35169), there was a dramatic reduction in incidence and degree of clinical scores within five days. AEG35169 is a mouse analogue of Aegera's current clinical candidate, AEG35156, a second-generation antisense oligonucleotide designed to block the cellular synthesis of XIAP.
o Aegis Therapeutics ...
Related newspaper, magazine, and journal articles:
|
|
Article: Discount Carrier JetBlue to Add Third Daily San ...
Knight Ridder/Tribune Business News;
July 15, 2003 ;
700+ words
... ... during the first weeks of its San Diego to New York service, JetBlue Airways yesterday ... full since we began flights to San Diego," company spokeswoman Fiona ... low-cost JetBlue began its San Diego-New York service on June 26, adding a ...
|
|